<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03000101</url>
  </required_header>
  <id_info>
    <org_study_id>RBSI14LHMB</org_study_id>
    <secondary_id>SIR Programme no. RBSI14LHMB</secondary_id>
    <nct_id>NCT03000101</nct_id>
  </id_info>
  <brief_title>Study of the Role of Pomegranate Juice Ellagitannins in the Modulation of Inflammation in Inflammatory Bowel Diseases</brief_title>
  <acronym>POME2016</acronym>
  <official_title>New Insight and Knowledge on Anti-inflammatory Effectiveness of Dietary Phenolics (NIKE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Bologna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Conserve Italia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gat Foods</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this research is to study the effects of a pomegranate juice on calprotectin
      levels in patients suffering of inflammatory bowel diseases (IBD) in clinical remission.
      Fecal calprotectin levels, surrogate marker of mucosal inflammation, will be measured from
      baseline to 12 weeks later (end of intervention). Systemic and mucosal changes of biochemical
      and molecular inflammatory response markers will be also assessed.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in fecal calprotectin</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change from baseline in fecal neutrophil-derived protein calprotectin, surrogate marker of mucosal improvement, after 12 weeks of consumption of experimental or placebo beverage, in subjects affected by IBD in clinical remission.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in plasma concentration of ellagitannin metabolites</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change from baseline in plasma concentration of ellagitannin metabolites after 12 weeks of intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in circulating cytokines levels</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change from baseline in plasma levels of cytokines after 12 weeks of intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in circulating trimethylamine-N-oxide (TMAO) levels</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change from baseline in plasma levels of TMAO after 12 weeks of intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in gene expression levels in peripheral blood mononuclear cells (PBMC)</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change from baseline in expression levels of selected genes in PBMC by qPCR after 12 weeks of intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in gene expression levels in intestinal biopsies</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change from baseline in expression levels of selected genes in intestinal biopsies by qPCR after 12 weeks of intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in urinary ellagitannin metabolite excretion</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change from baseline in urinary ellagitannin metabolite excretion after 12 weeks of intervention.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Crohn's Disease</condition>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Pomegranate juice</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The pomegranate juice is 100% pomegranate juice, not from concentrate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo beverage</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo beverage consists in water added with sugar and citric acid.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>100% pomegranate juice</intervention_name>
    <description>125 mL of 100% pomegranate juice twice daily for 12 weeks</description>
    <arm_group_label>Pomegranate juice</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo beverage</intervention_name>
    <description>125 mL of placebo beverage twice daily for 12 weeks</description>
    <arm_group_label>Placebo beverage</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with Ulcerative Colitis (diagnosed on the base of clinic, endoscopic, and
             histologic criteria) in clinical remission (SCCAI = 0) from at least three months and
             in stable therapy (without therapeutic modifications in the three previous months)
             with mesalazine, immunomodulators and/or biologics.

          -  Patients affected by Crohn's Disease, particularly involving sigmoid colon and rectum
             (diagnosed on the base of clinic, endoscopic, and histologic criteria) in clinical
             remission (CDAI &lt; 150) from at least three months and in stable therapy (without
             therapeutic modifications in the three previous months) with mesalazine A,
             immunomodulators and/or biologics.

          -  Fecal calprotectin at baseline ≥ 100 μg/g.

          -  Signed informed consent.

        Exclusion Criteria:

          -  Patients affected by Ulcerative Colitis and Crohn's Disease with severe endoscopic
             disease activity (Ulcerative Colitis: Mayo Endoscopic Score = 3; Crohn's Disease:
             Simple Endoscopic Score SES-CD &gt; 15).

          -  Patients on steroid therapy in the two previous months.

          -  Patients in therapy with warfarin or other anticoagulants.

          -  Known or supposed hypersensitivity to fruit and/or juice of pomegranate.

          -  Women in fertile age which refuse to use contraceptives specified in the study (oral
             contraception, IUD) and breastfeed women.

          -  Diabetic patients and other patients with severe clinical conditions which the
             investigator consider to contraindicate patient participation at the study.

          -  Therapy modifications and/or assumption of experimental therapies within three months
             before the study inclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesca Danesi, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Agri-Food Sciences and Technologies, University of Bologna</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luigi Ricciardiello, MD, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Medical and Surgical Sciences, University of Bologna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrea Belluzzi, MD PhD</last_name>
    <phone>+390512143873</phone>
    <email>andrea.belluzzi@aosp.bo.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>U.O. Gastroenterologia - Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant'Orsola-Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eleonora Scaioli, MD PhD</last_name>
      <phone>+390512143873</phone>
      <email>eleonora.scaioli@aosp.bo.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Best WR, Becktel JM, Singleton JW. Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI). Gastroenterology. 1979 Oct;77(4 Pt 2):843-6.</citation>
    <PMID>467941</PMID>
  </reference>
  <reference>
    <citation>Biasi F, Astegiano M, Maina M, Leonarduzzi G, Poli G. Polyphenol supplementation as a complementary medicinal approach to treating inflammatory bowel disease. Curr Med Chem. 2011;18(31):4851-65. Review.</citation>
    <PMID>21919842</PMID>
  </reference>
  <reference>
    <citation>Costa F, Mumolo MG, Ceccarelli L, Bellini M, Romano MR, Sterpi C, Ricchiuti A, Marchi S, Bottai M. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut. 2005 Mar;54(3):364-8.</citation>
    <PMID>15710984</PMID>
  </reference>
  <reference>
    <citation>D'Incà R, Dal Pont E, Di Leo V, Ferronato A, Fries W, Vettorato MG, Martines D, Sturniolo GC. Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int J Colorectal Dis. 2007 Apr;22(4):429-37. Epub 2006 Jul 13.</citation>
    <PMID>16838143</PMID>
  </reference>
  <reference>
    <citation>D'Amore S, Vacca M, Graziano G, D'Orazio A, Cariello M, Martelli N, Di Tullio G, Salvia R, Grandaliano G, Belfiore A, Pellegrini F, Palasciano G, Moschetta A. Nuclear receptors expression chart in peripheral blood mononuclear cells identifies patients with Metabolic Syndrome. Biochim Biophys Acta. 2013 Dec;1832(12):2289-301. doi: 10.1016/j.bbadis.2013.09.006. Epub 2013 Sep 21.</citation>
    <PMID>24060638</PMID>
  </reference>
  <reference>
    <citation>Daperno M, D'Haens G, Van Assche G, Baert F, Bulois P, Maunoury V, Sostegni R, Rocca R, Pera A, Gevers A, Mary JY, Colombel JF, Rutgeerts P. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc. 2004 Oct;60(4):505-12.</citation>
    <PMID>15472670</PMID>
  </reference>
  <reference>
    <citation>D'Haens G, Ferrante M, Vermeire S, Baert F, Noman M, Moortgat L, Geens P, Iwens D, Aerden I, Van Assche G, Van Olmen G, Rutgeerts P. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 2012 Dec;18(12):2218-24. doi: 10.1002/ibd.22917. Epub 2012 Feb 16.</citation>
    <PMID>22344983</PMID>
  </reference>
  <reference>
    <citation>Espín JC, González-Barrio R, Cerdá B, López-Bote C, Rey AI, Tomás-Barberán FA. Iberian pig as a model to clarify obscure points in the bioavailability and metabolism of ellagitannins in humans. J Agric Food Chem. 2007 Dec 12;55(25):10476-85. Epub 2007 Nov 9.</citation>
    <PMID>17990850</PMID>
  </reference>
  <reference>
    <citation>Foell D, Frosch M, Sorg C, Roth J. Phagocyte-specific calcium-binding S100 proteins as clinical laboratory markers of inflammation. Clin Chim Acta. 2004 Jun;344(1-2):37-51. Review.</citation>
    <PMID>15149869</PMID>
  </reference>
  <reference>
    <citation>Geboes K, Riddell R, Ost A, Jensfelt B, Persson T, Löfberg R. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut. 2000 Sep;47(3):404-9.</citation>
    <PMID>10940279</PMID>
  </reference>
  <reference>
    <citation>Giménez-Bastida JA, Larrosa M, González-Sarrías A, Tomás-Barberán F, Espín JC, García-Conesa MT. Intestinal ellagitannin metabolites ameliorate cytokine-induced inflammation and associated molecular markers in human colon fibroblasts. J Agric Food Chem. 2012 Sep 12;60(36):8866-76. doi: 10.1021/jf300290f. Epub 2012 Apr 16.</citation>
    <PMID>22463485</PMID>
  </reference>
  <reference>
    <citation>Larrosa M, González-Sarrías A, Yáñez-Gascón MJ, Selma MV, Azorín-Ortuño M, Toti S, Tomás-Barberán F, Dolara P, Espín JC. Anti-inflammatory properties of a pomegranate extract and its metabolite urolithin-A in a colitis rat model and the effect of colon inflammation on phenolic metabolism. J Nutr Biochem. 2010 Aug;21(8):717-25. doi: 10.1016/j.jnutbio.2009.04.012. Epub 2009 Jul 18.</citation>
    <PMID>19616930</PMID>
  </reference>
  <reference>
    <citation>Marín M, María Giner R, Ríos JL, Recio MC. Intestinal anti-inflammatory activity of ellagic acid in the acute and chronic dextrane sulfate sodium models of mice colitis. J Ethnopharmacol. 2013 Dec 12;150(3):925-34. doi: 10.1016/j.jep.2013.09.030. Epub 2013 Oct 17.</citation>
    <PMID>24140585</PMID>
  </reference>
  <reference>
    <citation>Martin DA, Bolling BW. A review of the efficacy of dietary polyphenols in experimental models of inflammatory bowel diseases. Food Funct. 2015 Jun;6(6):1773-86. doi: 10.1039/c5fo00202h. Review.</citation>
    <PMID>25986932</PMID>
  </reference>
  <reference>
    <citation>Mesko B, Poliska S, Szegedi A, Szekanecz Z, Palatka K, Papp M, Nagy L. Peripheral blood gene expression patterns discriminate among chronic inflammatory diseases and healthy controls and identify novel targets. BMC Med Genomics. 2010 May 5;3:15. doi: 10.1186/1755-8794-3-15.</citation>
    <PMID>20444268</PMID>
  </reference>
  <reference>
    <citation>Miller CA, Corbin KD, da Costa KA, Zhang S, Zhao X, Galanko JA, Blevins T, Bennett BJ, O'Connor A, Zeisel SH. Effect of egg ingestion on trimethylamine-N-oxide production in humans: a randomized, controlled, dose-response study. Am J Clin Nutr. 2014 Sep;100(3):778-86. doi: 10.3945/ajcn.114.087692. Epub 2014 Jun 18.</citation>
    <PMID>24944063</PMID>
  </reference>
  <reference>
    <citation>Pellegrini N, Salvatore S, Valtueña S, Bedogni G, Porrini M, Pala V, Del Rio D, Sieri S, Miglio C, Krogh V, Zavaroni I, Brighenti F. Development and validation of a food frequency questionnaire for the assessment of dietary total antioxidant capacity. J Nutr. 2007 Jan;137(1):93-8. Erratum in: J Nutr. 2007 Jun;137(6):1499.</citation>
    <PMID>17182807</PMID>
  </reference>
  <reference>
    <citation>Rosillo MA, Sanchez-Hidalgo M, Cárdeno A, de la Lastra CA. Protective effect of ellagic acid, a natural polyphenolic compound, in a murine model of Crohn's disease. Biochem Pharmacol. 2011 Oct 1;82(7):737-45. doi: 10.1016/j.bcp.2011.06.043. Epub 2011 Jul 7.</citation>
    <PMID>21763290</PMID>
  </reference>
  <reference>
    <citation>Rosillo MA, Sánchez-Hidalgo M, Cárdeno A, Aparicio-Soto M, Sánchez-Fidalgo S, Villegas I, de la Lastra CA. Dietary supplementation of an ellagic acid-enriched pomegranate extract attenuates chronic colonic inflammation in rats. Pharmacol Res. 2012 Sep;66(3):235-42. doi: 10.1016/j.phrs.2012.05.006. Epub 2012 Jun 4.</citation>
    <PMID>22677088</PMID>
  </reference>
  <reference>
    <citation>Schoepfer AM, Trummler M, Seeholzer P, Seibold-Schmid B, Seibold F. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm Bowel Dis. 2008 Jan;14(1):32-9.</citation>
    <PMID>17924558</PMID>
  </reference>
  <reference>
    <citation>Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987 Dec 24;317(26):1625-9.</citation>
    <PMID>3317057</PMID>
  </reference>
  <reference>
    <citation>Snyder SM, Reber JD, Freeman BL, Orgad K, Eggett DL, Parker TL. Controlling for sugar and ascorbic acid, a mixture of flavonoids matching navel oranges significantly increases human postprandial serum antioxidant capacity. Nutr Res. 2011 Jul;31(7):519-26. doi: 10.1016/j.nutres.2011.06.006.</citation>
    <PMID>21840468</PMID>
  </reference>
  <reference>
    <citation>Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 2000 Jul;119(1):15-22.</citation>
    <PMID>10889150</PMID>
  </reference>
  <reference>
    <citation>Valerii MC, Ricci C, Spisni E, Di Silvestro R, De Fazio L, Cavazza E, Lanzini A, Campieri M, Dalpiaz A, Pavan B, Volta U, Dinelli G. Responses of peripheral blood mononucleated cells from non-celiac gluten sensitive patients to various cereal sources. Food Chem. 2015 Jun 1;176:167-74. doi: 10.1016/j.foodchem.2014.12.061. Epub 2014 Dec 23.</citation>
    <PMID>25624220</PMID>
  </reference>
  <reference>
    <citation>Walmsley RS, Ayres RC, Pounder RE, Allan RN. A simple clinical colitis activity index. Gut. 1998 Jul;43(1):29-32.</citation>
    <PMID>9771402</PMID>
  </reference>
  <reference>
    <citation>Wilson A, Teft WA, Morse BL, Choi YH, Woolsey S, DeGorter MK, Hegele RA, Tirona RG, Kim RB. Trimethylamine-N-oxide: A Novel Biomarker for the Identification of Inflammatory Bowel Disease. Dig Dis Sci. 2015 Dec;60(12):3620-30. doi: 10.1007/s10620-015-3797-3. Epub 2015 Jul 10. Erratum in: Dig Dis Sci. 2016 Jan;61(1):325.</citation>
    <PMID>26160437</PMID>
  </reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2016</study_first_submitted>
  <study_first_submitted_qc>December 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2016</study_first_posted>
  <last_update_submitted>December 19, 2016</last_update_submitted>
  <last_update_submitted_qc>December 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi</investigator_affiliation>
    <investigator_full_name>andrea belluzzi, MD phD</investigator_full_name>
    <investigator_title>Andrea Belluzzi, MD PhD</investigator_title>
  </responsible_party>
  <keyword>Biomarkers</keyword>
  <keyword>Colitis</keyword>
  <keyword>Colitis, Ulcerative</keyword>
  <keyword>Colonic Diseases</keyword>
  <keyword>Crohn Disease</keyword>
  <keyword>Digestive System Diseases</keyword>
  <keyword>Fruit</keyword>
  <keyword>Fruit and Vegetable Juices</keyword>
  <keyword>Gastroenteritis</keyword>
  <keyword>Gastrointestinal Diseases</keyword>
  <keyword>Humans</keyword>
  <keyword>Hydrolysable Tannins</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Inflammatory Bowel Diseases</keyword>
  <keyword>Intestinal Diseases</keyword>
  <keyword>Punicaceae</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

